---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-048888"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:30:55.172156+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements

## Summary
- Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.
- Stock closed above $1.00 minimum bid since March 21, 2025; company expects to meet continued listing criteria.
- Hearings Panel granted exception until April 15, 2025 to demonstrate compliance with bid price and equity rules.
- Believes it meets $2.5M stockholders' equity after $9M upfront from FXR asset sale to Eli Lilly.
- Expects potential $5M milestone within 12 months from FXR program upon Phase 2 trial commencement.

## SEC filing metadata
- accession: 0000950170-25-048888
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017025048888/0000950170-25-048888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017025048888/onvo-20250402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-048888
- JSON: https://secwatch.observer/filing/0000950170-25-048888.json
- Plain text: https://secwatch.observer/filing/0000950170-25-048888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.